Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis

INTRODUCTION: Bedaquiline, pretomanid and linezolid (BPaL) is a new all oral, 6-month regimen comprised of bedaquiline, the new drug pretomanid and linezolid, endorsed by the WHO for use under operational research conditions in patients with extensively drug-resistant tuberculosis (XDR-TB). We quant...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Christiaan, Rupert, Stephan, Setiawan, Ery, Mambetova, Elmira, Edo, Patience, Sugiharto, Jhon, Useni, Sani, Malhotra, Shelly, Cook-Scalise, Sarah, Pambudi, Imran, Kadyrov, Abdullaat, Lawanson, Adebola, van den Hof, Susan, Gebhard, Agnes, Juneja, Sandeep, Sohn, Hojoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739433/
https://www.ncbi.nlm.nih.gov/pubmed/34992077
http://dx.doi.org/10.1136/bmjgh-2021-007182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739433/
https://www.ncbi.nlm.nih.gov/pubmed/34992077
http://dx.doi.org/10.1136/bmjgh-2021-007182

Ejemplares similares